ADVERTISEMENT
Current Topics in Parkinson's Disease: Therapy Options, Management Challenges, and Reimbursement Considerations
This 3-part series offers perspectives on Parkinson's disease focused on the current landscape, therapeutic options, and reimbursement considerations from physician, pharmacist, and payer speakers.
This video series is sponsored by Sunovion Pharmaceuticals, Inc.
Speakers In This Series:
- Pharmacist Perspective—Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, is the Vice President of Clinical Programs and Services at WellDyne.
- Physician Perspective—Yasar Torres-Yaghi, MD, is the Director of the Parkinsonism and Dementia Clinic at the Lewy Body Dementia Association Research Center of Excellence, Co-Director of the Movement Disorders Fellowship at the Parkinson Foundation Center of Excellence, and Assistant Professor of Neurology at Georgetown University School of Medicine.
- Payer Perspective—Barney Spivack, MD, FACP, has long-term experience in the payer arena.
- Moderator—Winston Wong, PharmD, is the President of W-Squared Group.
Overview of Parkinson's Disease: What We Already Know
In part 1 of this video series, Yasar Torres-Yaghi, MD; Patty Taddei-Allen, PharmD; and Barney Spivack, MD, review the current understanding of Parkinson's disease and goals of treatment from the physician, pharmacist, and payer perspective. Watch part 1 here.
A Deeper Look at Therapeutic Management of Parkinson's Disease
In part 2 of this video series, Yasar Torres-Yaghi, MD; Patty Taddei-Allen, PharmD; and Barney Spivack, MD, take a deeper look at available therapeutic options for Parkinson's disease from the physician, pharmacist, and payer perspective. Watch part 2 here.
Reimbursement Considerations and Care Team Management for Parkinson’s Disease
In part 3 of this video series, Yasar Torres-Yaghi, MD; Patty Taddei-Allen, PharmD; and Barney Spivack, MD, review reimbursement and overall care team considerations for patients with Parkinson's disease from a physician, pharmacist, and payer perspective. Watch part 3 here.